EO2463 for Indolent Non-Hodgkin Lymphoma
This study is testing a new vaccine called EO2463 for people with indolent non-Hodgkin lymphoma (a slow-growing type of blood cancer), specifically follicular lymphoma or marginal zone lymphoma. Researchers want to see how safe EO2463 is and how well it works, both by itself and when given with other approved medicines like lenalidomide and/or rituximab. You might be able to join if you are 18 or older, have follicular lymphoma or marginal zone lymphoma that has come back or not responded to at least one previous treatment, and have a good general health status (ECOG performance status 0-2). The study will look at how many people respond to the treatment and how many have a complete response (meaning the cancer is no longer detectable) over 24 months. The study plans to enroll 80 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 80 participants, but the phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will assess adverse events and treatment responses for up to 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
At a glance
Conditions
Where it's being run
12 sites across 7 statesStudy leadership
- Jan Fagerberg, MD · STUDY_DIRECTOR · Enterome
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment |Up to 24 months
Incidences of adverse events, Treatment-Emergent Adverse events, Serious Adverse Events, Deaths, and Laboratory Abnormalities Using the National Cancer Institute-Common Terminology Criteria for Adverse events (NCI-CTCAE) V5.0.
- Phase 2: Overall Response RateUp to 24 months
Overall Response Rate According to the Lugano Classification 2014 during EO2463 Monotherapy
- Phase 2: Complete Response RateUp to 24 months
Complete remission (CR)-rate according to the Lugano Classification 2014 during therapy with the combination of EO2463/lenalidomide/rituximab.